Vaccines against components of the renin-angiotensin system
Author
dc.contributor.author
Garay Gutiérrez, Noé Francisco
Author
dc.contributor.author
Hernández Fuentes, Carolina
Author
dc.contributor.author
García Rivas, Gerardo
Author
dc.contributor.author
Lavandero González, Sergio
Author
dc.contributor.author
Guerrero Beltrán, Carlos Enrique
Admission date
dc.date.accessioned
2021-04-05T16:55:11Z
Available date
dc.date.available
2021-04-05T16:55:11Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Heart Fail Rev . 2020 Sep 29;1-16
es_ES
Identifier
dc.identifier.other
10.1007/s10741-020-10033-1
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/178912
Abstract
dc.description.abstract
Even though effective drugs for treating hypertension are available, a great percentage of patients have inadequate control of their blood pressure. Unwanted side effects and inappropriate oral drug adherence are important factors that contribute to the global problem of uncontrolled hypertension. Vaccination could provide a revolutionary therapy with long-lasting effects, increasing patient compliance and therefore better control of high blood pressure. Nowadays, current immunization approaches against hypertension target renin, angiotensin I, angiotensin II, and angiotensin II type 1 receptor, key elements of the renin-angiotensin system. This article reviews the different vaccination attempts with proteins and peptides against the different molecules of the renin-angiotensin system in the last two decades, safety issues, and other novel prospects biomarkers in hypertension, and summarizes the potential of this immunomodulatory approach in clinical practice.
es_ES
Patrocinador
dc.description.sponsorship
Cardiovascular Medicine Research Group-Tecnologico de Monterrey
0020CAT131
Agencia Nacional de Investigación y Desarrollo (ANID), Chile: FONDAP
15130011